Biodexa Pharmaceuticals Plc
Research Biodexa Pharmaceuticals Plc (BDRX) on Bullrun: market cap USD 880.40K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBDRX
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 880.40K
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 880.40K.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 880.40K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.13M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.71M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.04M | n/a | n/a | n/a |
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biodexa Pharmaceuticals Plc's market cap?
Biodexa Pharmaceuticals Plc's market capitalization is USD 880.40K.
What does Biodexa Pharmaceuticals Plc do?
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.